Yahoo! Finance Search - Finance Home - Yahoo! - Help

Wednesday, May 22 2013 9:36pm ET - U.S. Markets Closed.
Industry Center - Drug Manufacturers - Other
Industry Center > Drug Manufacturers - Other > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Drug Manufacturers - Other News
Latest News
Wednesday, May 22, 2013
·Favorable Verdict for Mylan
Zacks.com - Wed 6:10 pm ET
·Will Ranbaxy Labs Be Excluded From Medicare And Medicaid?
at Forbes.com - Wed 6:04 pm ET
·Cubist Pharmaceuticals Inc. (CBST): Today's Featured Health Care Winner
at TheStreet.com - Wed 5:00 pm ET
·Orexigen Therapeutics' CEO Presents at 2013 UBS Global Healthcare Services Conference (Transcript)
- Wed 4:29 pm ET
·Apricus Biosciences Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire - Wed 4:01 pm ET
·Warner Chilcott Stock Falls On Unusually High Volume (WCRX)
at TheStreet.com - Wed 3:24 pm ET
·These 2 Patents Could Mean Everything Or Nothing
at Seeking Alpha - Wed 11:29 am ET
·United Reaches New 52-Week High (UTHR)
at TheStreet.com - Wed 10:35 am ET
·Protalex's PRTX-100 in rheumatoid arthritis receives positive Phase 1B review
- Wed 8:33 am ET
·Protalex Reports Positive Interim Review of Phase 1b Trial of PRTX-100 in Rheumatoid Arthritis by Independent Data Safety Monitoring Committee
Business Wire - Wed 8:30 am ET
·Aegerion's Pricing Power Sends Shares Flying
at Seeking Alpha - Wed 6:29 am ET
·Amarin announces patent allowance related to combination of Vascepa, Statin
- Wed 6:07 am ET
·Amarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin Therapy
GlobeNewswire - Wed 6:00 am ET
·Cumberland Pharma On The Right Track... But Moving Slowly
at Seeking Alpha - Wed 4:38 am ET
Tuesday, May 21, 2013
·The Deal: Actavis Extends Gains Following Warner Deal
at TheStreet.com - Tue 3:31 pm ET
·LipiGesic® M Migraine Treatment Product Shown to be as Effective as Prescription Based Medications
PR Newswire - Tue 2:33 pm ET
·Warner Chilcott Reaches New 52-Week High (WCRX)
at TheStreet.com - Tue 2:09 pm ET
·Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide
at Seeking Alpha - Tue 1:41 pm ET
·Cubist Rises On Unusually High Volume (CBST)
at TheStreet.com - Tue 12:25 pm ET
·Elite Pharmaceuticals Announces Change in Executive Leadership
GlobeNewswire - Tue 11:49 am ET
More Latest News...
Sponsor Results
Next Break-Out Stock?
Making Big Moves in Huge Industry, Price Could Jump--Learn More!
www.OTCStockPick.com
$2,000 - $10,000 Loans
Repayment Up To 60 Months. Get Cash Next Day. Apply Online, Sign Later
ClickNLoan.com
2.13% Mortgage Refinance
$160,000 Mortgage for $601/Mo. Secure. No Hidden Fees. 3.0% APR
eLendingSaver.com
(What's This?)
  

RSS Feeds

Add headlines to your
personalized My Yahoo! Page
( About My Yahoo! and RSS )

Drug Manufacturers - Other Headlines
More Finance RSS Feeds

Copyright © 2013 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2013 Morningstar, Inc. All Rights Reserved. Company information © 2013 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2013, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo! nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo! site, a user agrees not to redistribute the information found therein.
Questions or Comments?